<div id="readability-page-1"><div><p>Health-care companies rose after one potential breakthrough on a brain disease.</p><p>    Bristol Myers Squibb rallied after the biopharmaceutical company said that it was adding patients for its study on its drug, Cobenfy, to treat psychosis in patients with Alzheimer's disease. </p><p>    Shares of Eisai, which produces Alzheimer's treatment Leqembi in collaboration with Biogen, fell slightly. </p><p>   Write to Rob Curran at rob.curran@dowjones.com </p><p>    (END) Dow Jones Newswires</p><p>12-03-25 1736ET</p></div></div>

百時美施貴寶

<p>醫療保健公司在一項針對腦部疾病的潛在突破後上漲。百時美施貴寶在生物製藥公司表示將增加其針對阿爾茨海默病患者精神病治療藥物 Cobenfy 的研究患者後，股價上漲。與 Biogen 合作生產阿爾茨海默病治療藥物 Leqembi 的 Eisai 股價略微下跌。請聯繫 Rob Curran，郵箱為 rob.curran@dowjones.com (完) 道瓊斯新聞社 12-03-25 1736ET</p>

醫療保健因對阿爾茨海默症的希望而上漲 - 醫療保健綜述